The effect of Neuragen® on neuropathic pain: Double-blind, placebo-controlled clinical trial

Completed

• Conditions: Peripheral neuropathy; Nervous System Diseases; Other disorders of nervous system in diseases classified elsewhere

• Registration Number: ISRCTN20181108
• Lead Sponsor: Origin BioMed, Inc. (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06-09
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Both males and females, over 21
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3-8 on a 0-10 visual pain scale
4. Does not have mental and communication impairments

Exclusion Criteria

1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Foot sole pain on 11-point numerical pain scale, measured 30 minutes before and after the Neuragen®/placebo application, and tracked every hour for 8 hours.

Secondary Outcome Measures

Name	Time	Method
Duration of pain reduction. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours.